New combo therapy shows promise for advanced skin cancer patients

NCT ID NCT04889118

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma who haven't had prior treatment. It involved 131 Chinese participants with stage III or IV melanoma that could not be removed by surgery. The goal was to see if the combination helps delay cancer growth or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT MELANOMA

Contacts and locations

Locations

Beijing Cancer Hospital (0601)

Beijing, Beijing Municipality, 100036, China
Fudan University Shanghai Cancer Center ( Site 0607)

Shanghai, Shanghai Municipality, 200032, China
Fujian Provincial Cancer Hospital ( Site 0612)

Fuzhou, Fujian, 350014, China
Henan Cancer Hospital ( Site 0610)

Zhengzhou, Henan, 450003, China
Nanjing Drum Tower Hospital (0609)

Nanjing, Jiangsu, 210008, China
Sir Run Run Shaw Hospital (0605)

Hangzhou, Zhejiang, 310018, China
Sun Yat-Sen University Cancer Center (0602)

Guangzhou, Guangdong, 510000, China
The First Hospital Of Jilin University (0603)

Changchun, Jilin, 130021, China
Tianjin Medical University Cancer Institute & Hospital (0606)

Tianjin, Tianjin Municipality, 300060, China
Yunnan Cancer Hospital (0604)

Kunming, Yunnan, 430030, China
Zhejiang Cancer Hospital ( Site 0608)

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.